Continuous biomarkers are common for disease screening and diagnosis. To reach a dichotomous clinical decision, a threshold would be imposed to distinguish subjects with disease from non-diseased individuals. Among various performance metrics for a continuous biomarker, specificity at a controlled sensitivity level (or vice versa) is often desirable for clinical utility since it directly targets where the clinical test is intended to operate. Covariates, such as age, race, and sample collection, could impact the controlled sensitivity level in subpopulations and may also confound the association between biomarker and disease status. Therefore, covariate adjustment is important in such biomarker evaluation. In this paper, we suggest to adopt a parsimonious quantile regression model for the diseased population, locally at the controlled sensitivity level, and assess specificity with covariate-specific control of the sensitivity. Variance estimates are obtained from a sample-based approach and bootstrap. Furthermore, our proposed local model extends readily to a global one for covariate adjustment for the receiver operating characteristic (ROC) curve over the sensitivity continuum. We demonstrate computational efficiency of this proposed method and restore the inherent monotonicity in the estimated covariate-adjusted ROC curve. The asymptotic properties of the proposed estimators are established. Simulation studies show favorable performance of the proposal. Finally, we illustrate our method in biomarker evaluation for aggressive prostate cancer.
翻译:持续生物标志对于疾病筛查和诊断来说很常见。为了达到诊断疾病诊断的分解临床决定,将规定一个门槛,将疾病对象与非疾病个人区分开来。在连续生物标志的各种性能衡量标准中,在控制敏感度水平(或反之亦然)的特性对于临床效用来说往往是可取的,因为它直接针对临床试验的运行目标。年龄、种族和样本收集等差异性能会影响亚人群的受控敏感度,并可能混淆生物标志和疾病状况之间的联系。因此,在生物标志评估中,共变式调整很重要。在本文件中,我们建议对疾病人群采用一种可连续生物标志的微量回归模型,在控制敏感度水平上,对具有受控敏感度的敏感度水平进行共变异性控制,评估其特性。差异性估计来自基于抽样的方法和靴系。此外,我们提议的本地模型可轻易扩展为全球对接收器操作特征(ROC)曲线进行共变式调整。我们建议采用这一方法的计算效率,并恢复疾病人群的内在惯性弹性性状态评估。我们提议的模型的精确性分析方法。